CapsoVision Inc. (NASDAQ:CV) is up 1.83% intraday at $7.22 as investors accumulate ahead of a pending FDA 510(k) decision on its AI-assisted CapsoCam Plus reading module, with analyst targets implying more than 50% upside.

Key Highlights

• CapsoVision is trading at $7.22, up 1.83% intraday, recovering from an opening low of $7.09 to near the session high of $7.25 in a clean accumulation pattern.

• A 510(k) submission to the FDA for an AI-assisted reading module for CapsoCam Plus is the primary near-term catalyst, with US commercialisation targeted on clearance around mid-2026.

• Q1 2026 revenue was stable at $2.8 million with a $14 million private placement reinforcing the balance sheet ahead of the regulatory decision.

• Roth MKM rates the stock Buy with a $11 price target, implying more than 50% upside; Benchmark carries a Speculative Buy.

Intraday Recovery Signals Positioning Ahead of FDA Decision

CapsoVision Inc. (NASDAQ:CV), a Saratoga, California-based commercial-stage medical technology company developing AI-enabled capsule endoscopy systems, is trading at $7.22 today, up 1.83% on the session. The stock opened at $7.09 and has recovered steadily to near the session high of $7.25, a clean intraday reversal that reflects consistent buying interest ahead of a live regulatory catalyst.

No same-day company announcement accompanies the move. The underlying driver is CapsoVision's pending 510(k) application to the FDA for a proprietary AI-assisted reading module for its flagship CapsoCam Plus platform, designed to improve detection of clinically significant GI pathology and compress clinician review time. The company has targeted mid-2026 for clearance, placing the decision within the current quarter.

CapsoCam Plus and the AI Reading Module

The CapsoCam Plus system is deployed across small bowel and colon visualisation in gastroenterology practices and hospitals. Standard capsule endoscopy studies generate thousands of image frames requiring hours of physician review. CapsoVision's AI reading module is designed to triage that image stream automatically, flagging clinically significant findings and reducing effective review time substantially.

A successful 510(k) clearance would position CapsoVision as one of the first capsule endoscopy platforms with a commercially cleared AI reading tool in the US, a differentiation that could accelerate adoption in high-volume GI practices where throughput efficiency drives procurement decisions.

Financials and Balance Sheet

Q1 2026 revenue held steady at $2.8 million, with strong utilisation and expanding clinical adoption across the installed base. A $14 million private placement completed in 2026 reinforced the balance sheet, reducing near-term capital-raise risk and providing runway through the FDA review window.

Roth MKM carries a Buy rating with a $11 price target, implying upside of more than 50% from the current intraday level. Benchmark holds a Speculative Buy. Both reflect a scenario in which FDA clearance arrives on schedule and the AI reading module begins generating incremental revenue within 2026.

Key Risk: Binary Regulatory Outcome

The central risk is the binary nature of the 510(k) decision. Clearance would likely drive a material re-rating toward analyst targets. A delay or additional information request from the FDA would pressure the stock near term. At $7.22, the market is pricing a reasonable probability of on-schedule clearance, and any extension of the review window should be treated as a risk event.